asymmetrical hypertrophy of the heart.' In a footnote, he noted the recent sudden death of the brother of one of the original cases, thus identifying the familial nature of this condition. The subsequent report2 of two generations of the family of these two siblings showed that asymmetrical hypertrophy was inherited in a manner consistent with an autosomal dominant trait. The term "obstructive cardiomyopathy" was proposed for these and similar cases, identifying this as a heart muscle disorder. The description of this family initiated the detailed characterisation of this novel syndrome, which was Recent advances in molecular biology have led to the identification of the gene defects responsible for several important inherited conditions, even where there was no prior knowledge of any defect at the protein level (reviewed in reference9). In the absence of any apparent candidate genes or of any known cytogenetic abnormality in familial hypertrophic cardiomyopathy, the approach that was adopted was the use of linkage analysis. Linkage analysis depends upon the demonstration of "co-segregation" of a disease trait with a DNA polymorphism of known chromosomal location. If a DNA polymorphism is situated close to the disease gene on a given chromosome, then the presence of the polymorphism at this site will tend to be inherited with the disease trait in a family pedigree. Where screened in this way. The analysis showed evidence of a sequence mismatch in exon 14 in this individual. A similar analysis of the remaining family members showed this abnormality in all affected members (fig 2) . In contrast, this mismatch was not present in unaffected family members. The association of this abnormality in myosin with the disease shows linkage of the familial hypertrophic cardiomyopathy trait to the MHC locus in this family, with a LOD score (logarithm of the odds) of 3 9 (odds of almost 10 000 to 1 in favour of linkage). This abnormality in exon 14, which shows complete concordance with disease status throughout the family and which to date has not been seen in unaffected individuals, is the likely candidate for being the disease-causing mutation. Further characterisation of this defect will establish the precise abnormality in MHC gene and its polypeptide structure.
Implications of genetic diagnosis
The detection of an abnormality within the f myosin heavy chain gene in a family such as this makes the subsequent diagnosis of disease state very simple in any family member. The diagnosis can be made definitively in children and adolescents in these families and also in those adults who are difficult to diagnose clinically.'2 Similarly, unaffected individuals can be told with certainty that they and their offspring will remain free of the condition, thereby avoiding the need for serial clinical screening. Although the surviving members of this family all have had correctly assigned clinical diagnoses it is noteworthy that sudden death has been the presenting feature in this family in the past. provide more than a means of definitive diagnosis-by also providing a prognostic indicator. There is considerable variability in the severity of familial hypertrophic cardiomyopathy among different families, with some (such as the family Teare studied) showing far greater morbidity and mortality than others.' '5 Despite the acknowledged variability of expression within a given family,'6 such trends that characterise a particular family are most likely to result from the influence ofthe specific disease-causing mutation. As more disease-causing mutations are identified, a genetic classification is becoming available for some familial hypertrophic cardiomyopathy families, so that it is now possible to begin determining the influence of the type of mutation on the natural history (Watkins et al. Unpublished). The clinical features of unrelated families sharing a particular mutation can be compared with those of individuals with different mutations within the MHC genes and with those with non-myosin defects, to detect any predictive associations with particular mutation types.
In conclusion, genetic diagnosis in an individual or in a family is becoming a practical proposition and is likely to affect profoundly the management of this condition, both in terms of early diagnosis and risk stratification. Identification of the remaining disease-causing gene(s) in familial hypertrophic cardiomyopathy may be possible by investigating the genes for other cardiac contractile proteins. A complete genetic classification will then be available to determine the full spectrum of manifestations of familial hypertrophic cardiomyopathy. Unresolved issues such as the nature of apparently similar clinical syndromes'7 and the frequency and origins of sporadic disease, will be clarified. Moreover, in addition to the expected clinical benefits of these findings, the documentation of disease-causing mutations in the ft cardiac MHC gene will provide insights into myosin structure-function relations that will have impact in wider areas of basic science research. 
